Approximately 2,000 US cases of malaria are diagnosed annually. Without appropriate treatment, about 15 percent become severe. Mortality from untreated severe malaria (particularly cerebral malaria) approaches 100 percent.
On Tuesday, the Food and Drug Administration (FDA) approved Artesunate for Injection to Amivas, a Maryland company specializing in treatments for rare and neglected tropical diseases.
Joining me today to talk about severe malaria and the newly approved drug is Bryan Smith, MD. Dr. Smith is the Chief Medical Officer at Amivas.
Show notes:
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Stitcher | RSS
Related podcasts:
Malaria series: Plasmodium malariae, P. ovale and the monkey malaria- Plasmodium knowlesi
Plasmodium falciparum, cerebral malaria and blackwater fever
Malaria: A general introduction and Plasmodium vivax
Malaria drug resistance: An alternative for detection in the field
Malaria epidemic in Venezuela: 2.5 million cases predicted for 2020
Venezuela epidemics: From measles to malaria with Dr. Alberto Paniz-Mondolfi
Dengue in 2019, the vaccines and the quest for a World Dengue Day
Dr. Mike Osterholm on COVID-19 testing, death rates and more
SARS-CoV-2 transmission in cats: A study
One thought on “Severe malaria treatment receives FDA approval”